Investing

Cramer: Promising data from coronavirus drug trial ‘beginning of the end of the true nightmare’

Jim Cramer

Scott Mlyn | CNBC

CNBC’s Jim Cramer said Wednesday that positive news from Gilead Sciences about a potential treatment for the coronavirus marked a turning point in the fight against Covid-19.

“What I regard this as is the beginning of the end of the true nightmare, which is that it’s a death sentence,” Cramer said on “Squawk Box.”

U.S. stocks soared on Wednesday after Gilead indicated it was seeing positive, preliminary signs about the effectiveness of its antiviral remdesivir in treating coronavirus patients.

Cramer has been hopeful about remdesivir as a possible treatment.

Last week, the “Mad Money” host said, he believes that scientists testing treatments for the coronavirus will succeed in getting patients “out of the hospital faster” and reducing “death sentence” concerns.

On Thursday, Cramer said at the time, “I do feel better about what Gilead is doing.”

Products You May Like

Articles You May Like

Frontier Airlines CEO urges crackdown of ‘rampant abuse’ of airport wheelchair service
The 10 books the rich will be reading this summer
Citi elevates GE Healthcare to a top pick. Here’s why we’re not buying more shares just yet
Boeing expects a 2024 cash burn, slow recovery of airplane deliveries amid crisis, CFO says
Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supply

Leave a Reply

Your email address will not be published. Required fields are marked *